| Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction N Singh, YG Lee, O Shestova, P Ravikumar, KE Hayer, SJ Hong, XM Lu, ... Cancer discovery 10 (4), 552-567, 2020 | 221 | 2020 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 155 | 2022 |
| Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells N Singh, NV Frey, B Engels, DM Barrett, O Shestova, P Ravikumar, ... Nature medicine 27 (5), 842-850, 2021 | 109 | 2021 |
| Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, ... Annals of Oncology 33 (9), 916-928, 2022 | 42 | 2022 |
| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... Cancer discovery 12 (10), 2372-2391, 2022 | 30 | 2022 |
| T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy G Ghilardi, JA Fraietta, JN Gerson, VM Van Deerlin, JJD Morrissette, ... Nature Medicine, 1-6, 2024 | 29 | 2024 |
| Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy M Uribe-Herranz, S Beghi, M Ruella, K Parvathaneni, S Salaris, ... Molecular Therapy 31 (3), 686-700, 2023 | 16 | 2023 |
| CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells I Chun, KH Kim, YH Chiang, W Xie, YGG Lee, R Pajarillo, A Rotolo, ... Blood 136, 51-52, 2020 | 15 | 2020 |
| Apoptosis: a Janus bifrons in T-cell immunotherapy YG Lee, N Yang, I Chun, P Porazzi, A Carturan, L Paruzzo, CT Sauter, ... Journal for Immunotherapy of Cancer 11 (4), 2023 | 8 | 2023 |
| Bendamustine is a safe and effective regimen for lymphodepletion before tisagenlecleucel in patients with large B-cell lymphomas G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, ... Blood 138, 1438, 2021 | 5 | 2021 |
| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov 2022; 12: 2372–91. doi: 10.1158/2159 … YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... CD-21-1026, 0 | 5 | |
| Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 29 (11), 2954-2954, 2023 | 4 | 2023 |
| Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines G Ghilardi, L Paruzzo, J Svoboda, EA Chong, AA Shestov, L Chen, ... Blood Advances 8 (3), 653-666, 2024 | 3 | 2024 |
| Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on-and off-rates against non-Hodgkin … Y Zhang, RP Patel, KH Kim, H Cho, JC Jo, SH Jeong, SY Oh, YS Choi, ... Molecular cancer 22 (1), 200, 2023 | 3 | 2023 |
| Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ … RP Patel, G Ghilardi, P Porazzi, S Yang, D Qian, R Pajarillo, M Wang, ... Blood 140 (Supplement 1), 1604-1605, 2022 | 3 | 2022 |
| The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies M Smith, A Dai, G Ghilardi, K Amelsberg, SM Devlin, R Pajarillo, ... Blood 138, 253, 2021 | 3 | 2021 |
| CAR T-cell immunotherapy in minority patients with lymphoma G Ghilardi, S Williamson, R Pajarillo, L Paruzzo, L Chen, C Grady, ... NEJM evidence 3 (4), EVIDoa2300213, 2024 | 2 | 2024 |
| Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy Y Tang, W Liu, S Kadu, O Johnson, ZS Hasanali, A Kelly, A Shestov, ... Blood 143 (2), 139-151, 2024 | 1 | 2024 |
| Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms MG Angelos, RP Patel, YH Chiang, W Xie, R Pajarillo, CE Shaw, E Singh, ... Blood 142, 885, 2023 | 1 | 2023 |
| BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY CYTOKINES AND DECREASED TOXICITIES AFTER BOTH 4‐1BB‐AND CD28‐COSTIMULATED CART19 FOR NON‐HODGKIN LYMPHOMA. G Ghilardi, L Paruzzo, J Svoboda, EA Chong, IJ Cohen, SD Nasta, ... Hematological Oncology 41, 2023 | 1 | 2023 |
Marco Ruella, MDUniversity of PennsylvaniaVerified email at upenn.edu
